Eyebright Medical(688050)

Search documents
爱博医疗收盘上涨1.52%,滚动市盈率40.36倍,总市值152.60亿元
Sou Hu Cai Jing· 2025-08-25 11:48
Company Overview - Aibo Medical's closing price on August 25 was 78.9 yuan, with an increase of 1.52%, resulting in a rolling PE ratio of 40.36 times and a total market value of 15.26 billion yuan [1] - The company ranks 77th in the medical device industry, which has an average PE ratio of 56.14 times and a median of 40.36 times [1] Institutional Holdings - As of the first quarter of 2025, 18 institutions hold shares in Aibo Medical, all of which are funds, with a total holding of 11.0688 million shares valued at 762 million yuan [1] Business Operations - Aibo Medical focuses on the independent research, production, sales, and related services of ophthalmic medical devices, with main products including artificial lenses, surgical products, orthokeratology lenses, myopia control products, contact lenses, and other vision care products [1] Financial Performance - In the latest quarterly report for Q1 2025, Aibo Medical achieved an operating revenue of 357 million yuan, representing a year-on-year increase of 15.07%, while net profit was 92.5581 million yuan, showing a year-on-year decrease of 10.05%, with a gross profit margin of 64.60% [1]
爱博医疗8月25日现6笔大宗交易 总成交金额1943.4万元 其中机构买入423.75万元 溢价率为-7.40%
Xin Lang Cai Jing· 2025-08-25 11:03
炒股就看金麒麟分析师研报,权威,专业,及时,全面,助您挖掘潜力主题机会! 8月25日,爱博医疗收涨1.52%,收盘价为78.90元,发生6笔大宗交易,合计成交量26.6万股,成交金额 1943.4万元。 第4笔成交价格为73.06元,成交3.00万股,成交金额219.18万元,溢价率为-7.40%,买方营业部为机构 专用,卖方营业部为国联民生证券股份有限公司北京金宝街证券营业部。 第5笔成交价格为73.06元,成交2.80万股,成交金额204.57万元,溢价率为-7.40%,买方营业部为机构 专用,卖方营业部为国联民生证券股份有限公司北京金宝街证券营业部。 第6笔成交价格为73.06元,成交10.00万股,成交金额730.60万元,溢价率为-7.40%,买方营业部为华泰 证券股份有限公司深圳益田路荣超商务中心证券营业部,卖方营业部为国联民生证券股份有限公司北京 金宝街证券营业部。 进一步统计,近3个月内该股累计发生27笔大宗交易,合计成交金额为1.5亿元。该股近5个交易日累计 上涨1.53%,主力资金合计净流出260.54万元。 责任编辑:小浪快报 第1笔成交价格为73.06元,成交5.00万股,成交金额36 ...
爱博医疗今日大宗交易折价成交26.6万股,成交额1943.4万元
Xin Lang Cai Jing· 2025-08-25 09:33
8月25日,爱博医疗大宗交易成交26.6万股,成交额1943.4万元,占当日总成交额的4.8%,成交价73.06元,较市场收盘价78.9元折价7.4%。 | 交易日期 | 证券简称 | 证券代码 | | | 成交价(元) 成交金额(万元) 成交量(*) 买入营业部 | | 卖出营业部 | | --- | --- | --- | --- | --- | --- | --- | --- | | 2025-08-25 | 爱博医疗 | 688050 | 73.06 | 730.6 | 10 | 华泰证券股份有限 | 国联民生证券股份 | | | | | | | | 公司深圳益田路荣 | 有限公司北京金宝 | | | | | | | | 超商务中心证券营 | 街证券营业部 | | | | | | | | 业部 | | | 2025-08-25 | 爱博医疗 | 688050 | 73.06 | 365.3 | ર | 中信证券股份有限 | 国联民生证券股份 | | | | | | | | 公司上海分公司 | 有限公司北京金宝 | | | | | | | | | 街证券营业部 | | 2025-08-25 | 爱博医疗 ...
【机构调研记录】长盛基金调研冰轮环境、莱特光电等4只个股(附名单)
Zheng Quan Zhi Xing· 2025-08-25 00:08
Group 1: Ice Wheel Environment (000811) - The company focuses on providing advanced system solutions and lifecycle services in the energy and power sectors, with products including compressors and heat exchangers operating in the temperature range of -271℃ to 200℃ [1] - In the first half of the year, the low-temperature refrigeration segment generated revenue of 1.73 billion yuan, accounting for 55% of total revenue, while the HVAC segment generated 1.2 billion yuan, accounting for 39% [1] - The company supplies cooling equipment for data centers, and its products have been included in the Ministry of Industry and Information Technology's directory of advanced applicable technologies for national green data centers [1] Group 2: Lite Optoelectronics - In the first half of 2025, the company achieved revenue of 292 million yuan, a year-on-year increase of 18.84%, and a net profit of 126 million yuan, up 36.74% year-on-year [2] - The growth is attributed to rising demand in the OLED market and the company's cost reduction and efficiency improvement efforts [2] - The company is expanding its OLED terminal materials product line and accelerating the construction of its 8.6-generation line, which is expected to significantly boost demand for organic light-emitting materials [2] Group 3: Opto - In the first half of 2025, the company reported revenue of 682.56 million yuan, a year-on-year increase of 30.68%, and a net profit of 145.99 million yuan, up 28.80% [3] - The company has made progress in the smart robotics sector and established a robotics division, enhancing its visual solution offerings [3] - The machine vision industry is projected to exceed 21 billion yuan in market size by 2025, with a compound annual growth rate of approximately 20% from 2024 to 2028 [3] Group 4: Longli Technology (300752) - The company experienced revenue growth in the first half of 2025, but profits declined due to increased capacity construction and personnel costs, leading to short-term operational pressure [4] - The company’s LIPO technology products have begun mass production, with the mobile phone project entering mass production in the third quarter [4] - As a leading player in Mini-LED technology for automotive displays, the company is positioned for rapid growth in this sector, with recent products featuring its Mini-LED technology [4] Group 5: Longsheng Fund - As of now, the fund has an asset management scale of 96.413 billion yuan, ranking 62nd among 210 funds, with 65.591 billion yuan in non-monetary public funds [5] - The fund manages 140 public funds and has 22 fund managers, ranking 55th and 63rd respectively [5] - The best-performing fund in the past year is the Longsheng Urbanization Theme Mixed A fund, with a net value increase of 110.67% [5]
医疗器械行业21日主力净流出5.96亿元,新华医疗、理邦仪器居前
Sou Hu Cai Jing· 2025-08-21 07:46
Group 1 - The medical device industry experienced a slight increase of 0.07% on August 21, with a net outflow of 596 million yuan in main capital [1] - Among the component stocks, 55 stocks rose while 41 stocks fell [1] - The companies with the highest net outflow of main capital included Xinhua Medical (11.58 million yuan), Libang Instruments (10.77 million yuan), and Jiukang Bio (10.73 million yuan) [1] Group 2 - The latest prices and performance of selected medical companies include: Meihua Medical at 23.41 with an increase of 8.09% and a net inflow of 6.44 million yuan [2] - Mindray Medical at 245.71 with an increase of 3.87% and a net inflow of 879.86 million yuan [2] - Other notable companies include Yingke Medical at 37.43 with an increase of 1.08% and a net inflow of 599.81 million yuan, and Aibo Medical at 77.31 with an increase of 1.15% and a net inflow of 4360.64 million yuan [2]
爱博医疗上周获融资净买入1720.87万元,居两市第470位
Sou Hu Cai Jing· 2025-08-17 23:51
8月18日,沪深两融数据显示,爱博医疗上周累计获融资净买入额1720.87万元,居两市第470位,上周 融资买入额2.51亿元,偿还额2.33亿元。 天眼查商业履历信息显示,爱博诺德(北京)医疗科技股份有限公司,成立于2010年,位于北京市,是一 家以从事医药制造业为主的企业。企业注册资本19340.3175万人民币,实缴资本18954.4528万人民币。 公司法定代表人为解江冰。 通过天眼查大数据分析,爱博诺德(北京)医疗科技股份有限公司共对外投资了20家企业,参与招投标项 目222次,知识产权方面有商标信息717条,专利信息165条,此外企业还拥有行政许可93个。 来源:金融界 爱博医疗所属概念板块包括:医疗器械、北京板块、专精特新、沪股通、上证380、融资融券、机构重 仓、医疗器械概念。 资金流方面,爱博医疗近5日主力资金流出1.18亿元,区间跌幅6.39%;近10日主力资金流出2.13亿元, 区间跌幅6.2%。 ...
医药生物周报(25年第31周):机接口政策频出,关注国内脑机接口产业链-20250816
Guoxin Securities· 2025-08-16 13:50
Investment Rating - The report maintains an "Outperform" rating for the pharmaceutical and biotechnology sector [5][39]. Core Insights - The pharmaceutical sector has shown stronger performance compared to the overall market, with a total A-share increase of 2.04% and a decline of 0.84% in the biotechnology sector [1][30]. - The brain-computer interface (BCI) industry is rapidly developing, supported by recent government policies and successful clinical trials, indicating significant growth potential [2][11]. - The report emphasizes the importance of innovative drugs and their supporting infrastructure, highlighting the positive impact of adjustments in medical insurance and commercial health insurance on domestic innovative drug sales [3][39]. Summary by Sections Market Performance - The overall A-share market increased by 2.04%, while the biotechnology sector decreased by 0.84%, indicating a weaker performance relative to the market [1][30]. - The current price-to-earnings (P/E) ratio for the pharmaceutical sector is 38.77x, which is at the 80.28th percentile of its historical valuation over the past five years [1][35]. Brain-Computer Interface Industry - The BCI industry is characterized by a growing number of supportive policies and technological advancements, with a focus on both invasive and non-invasive methods [2][11]. - The market for non-invasive BCIs is the primary research direction, accounting for 86% of the market share [11][16]. - The potential market size for serious medical applications of BCIs is estimated between $15 billion and $85 billion, while consumer medical applications could reach $25 billion to $60 billion [16]. Key Companies and Investment Recommendations - **Mindray Medical (300760.SZ)**: Rated "Outperform" with projected net profits increasing from 116.7 billion in 2024 to 161.9 billion in 2027 [4]. - **WuXi AppTec (603259.SH)**: Rated "Outperform" with expected net profits rising from 93.5 billion in 2024 to 145.1 billion in 2027 [4]. - **Aier Eye Hospital (300633.SZ)**: Rated "Outperform" with a focus on expanding its service network and enhancing service prices [39]. - **Huitai Medical (688617.SH)**: Rated "Outperform" with a strong focus on electrophysiology and interventional medical devices [40]. - **Innovative Medical (002173.SZ)**: Rated "Outperform" with ongoing clinical trials and expected registration of medical devices [39].
爱博医疗(688050)8月15日主力资金净流出3276.26万元
Sou Hu Cai Jing· 2025-08-15 12:46
金融界消息 截至2025年8月15日收盘,爱博医疗(688050)报收于76.99元,上涨0.96%,换手率 1.86%,成交量3.54万手,成交金额2.71亿元。 资金流向方面,今日主力资金净流出3276.26万元,占比成交额12.07%。其中,超大单净流出2294.44万 元、占成交额8.46%,大单净流出981.82万元、占成交额3.62%,中单净流出流入132.36万元、占成交额 0.49%,小单净流入3143.90万元、占成交额11.59%。 爱博医疗最新一期业绩显示,截至2025一季报,公司营业总收入3.57亿元、同比增长15.07%,归属净利 润9255.81万元,同比减少10.05%,扣非净利润8622.85万元,同比减少12.83%,流动比率4.480、速动比 率3.430、资产负债率24.61%。 天眼查商业履历信息显示,爱博诺德(北京)医疗科技股份有限公司,成立于2010年,位于北京市,是一 家以从事医药制造业为主的企业。企业注册资本19340.3175万人民币,实缴资本18954.4528万人民币。 公司法定代表人为解江冰。 通过天眼查大数据分析,爱博诺德(北京)医疗科技股份有限公司共 ...
爱博医疗收盘上涨1.97%,滚动市盈率41.05倍,总市值155.21亿元
Sou Hu Cai Jing· 2025-08-12 10:58
8月12日,爱博医疗今日收盘80.25元,上涨1.97%,滚动市盈率PE(当前股价与前四季度每股收益总和 的比值)达到41.05倍,创68天以来新低,总市值155.21亿元。 从行业市盈率排名来看,公司所处的医疗器械行业市盈率平均57.51倍,行业中值41.25倍,爱博医疗排 名第76位。 截至2025年一季报,共有18家机构持仓爱博医疗,其中基金18家,合计持股数1106.88万股,持股市值 7.62亿元。 来源:金融界 爱博诺德(北京)医疗科技股份有限公司的主营业务是眼科医疗器械的自主研发、生产、销售及相关服 务。公司的主要产品是人工晶状体、其他手术产品、角膜塑形镜、其他近视防控产品、隐形眼镜、其他 视力保健产品。 最新一期业绩显示,2025年一季报,公司实现营业收入3.57亿元,同比15.07%;净利润9255.81万元, 同比-10.05%,销售毛利率64.60%。 序号股票简称PE(TTM)PE(静)市净率总市值(元)13爱博医疗41.0539.966.34155.21亿行业平均 57.5153.344.97120.28亿行业中值41.2539.962.9558.75亿1九安医疗11.2611.38 ...
爱博医疗收盘上涨1.82%,滚动市盈率40.26倍,总市值152.21亿元
Sou Hu Cai Jing· 2025-08-11 11:57
Group 1 - The core viewpoint of the articles highlights the performance and valuation of Aibo Medical, which closed at 78.7 yuan with a PE ratio of 40.26, marking a new low in 13 days, and a total market capitalization of 15.221 billion yuan [1] - Aibo Medical ranks 78th in the medical device industry based on PE ratio, with the industry average at 56.56 and the median at 39.76 [1][2] - As of March 31, 2025, Aibo Medical has 9,729 shareholders, a decrease of 94 from the previous count, with an average holding value of 352,800 yuan and an average shareholding of 27,600 shares [1] Group 2 - Aibo Medical specializes in the research, production, sales, and related services of ophthalmic medical devices, with key products including artificial lenses, surgical products, orthokeratology lenses, myopia control products, contact lenses, and other vision care products [1] - In the latest quarterly report for Q1 2025, Aibo Medical reported revenue of 357 million yuan, a year-on-year increase of 15.07%, while net profit was 92.558 million yuan, reflecting a year-on-year decrease of 10.05%, with a gross margin of 64.60% [1]